Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Trexquant Investment LP

Trexquant Investment LP boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 241.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 300,548 shares of the company’s stock after purchasing an additional 212,552 shares during the period. Trexquant Investment LP owned approximately 0.33% of Arcus Biosciences worth $4,475,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. FMR LLC grew its holdings in shares of Arcus Biosciences by 6.9% during the third quarter. FMR LLC now owns 4,467,557 shares of the company’s stock valued at $68,309,000 after buying an additional 286,766 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Arcus Biosciences by 2.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 579,623 shares of the company’s stock valued at $8,631,000 after purchasing an additional 12,644 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Arcus Biosciences by 8.6% in the fourth quarter. Bank of New York Mellon Corp now owns 381,615 shares of the company’s stock worth $5,682,000 after purchasing an additional 30,290 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Arcus Biosciences by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 263,517 shares of the company’s stock worth $3,924,000 after purchasing an additional 7,906 shares during the period. Finally, Nordea Investment Management AB boosted its position in Arcus Biosciences by 2.5% in the fourth quarter. Nordea Investment Management AB now owns 218,930 shares of the company’s stock valued at $3,245,000 after buying an additional 5,246 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Bank of America reduced their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. Morgan Stanley decreased their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Finally, HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $30.25.

Arcus Biosciences Trading Down 4.2 %

RCUS stock opened at $6.87 on Friday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a 52-week low of $6.79 and a 52-week high of $18.98. The company’s 50-day simple moving average is $10.50 and its 200-day simple moving average is $14.00. The firm has a market cap of $722.30 million, a P/E ratio of -2.18 and a beta of 1.54.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.17) by $0.14. The company had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. As a group, equities analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Yasunori Kaneko acquired 20,000 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the purchase, the director now owns 28,400 shares in the company, valued at approximately $285,704. This represents a 238.10 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Terry J. Rosen bought 19,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was purchased at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares of the company’s stock, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by company insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.